Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer, and Brian Blakey, Chief Business Officer, will participate in a fireside chat at the Baird Biotech Discovery Series on Tuesday, December 5, 2023, at 11:30 AM ET. Stealth leadership will be joined by Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, to discuss data from the Company’s Phase 2 ReCLAIM-2 trial of elamipretide in dry age-related macular degeneration (dry AMD) and provide an update on Phase 3 development plans. To register for the webcast, please visit the registration page here. A replay of the webcast will be available through Baird for a limited time following the event. About Stealth The Company is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. The Company is progressing its lead product candidate, elamipretide, into Phase 3 clinical trials in dry age-related macular degeneration and through the pivotal NuPOWER trial in nPMM, as well as continuing regulatory engagement on its Phase 3 data in Barth syndrome, an ultra-rare cardioskeletal disease. The Company is evaluating its second-generation clinical-stage candidate, SBT-272, for ophthalmic and neurological disease indications following promising preclinical data. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates. ChatGPT
Title: “Stealth BioTherapeutics Announces Participation in Baird Biotech Discovery Series Fireside Chat”
Description: Explore the latest developments from Stealth BioTherapeutics Inc., a clinical-stage biotechnology company at the forefront of discovering, developing, and commercializing innovative therapies for diseases linked to mitochondrial dysfunction. The company’s Chief Executive Officer, Reenie McCarthy, and Chief Business Officer, Brian Blakey, are set to engage in a fireside chat at the Baird Biotech Discovery Series on December 5, 2023, at 11:30 AM ET.
This insightful discussion will also feature Dr. Arshad Khanani, Director of Clinical Research at Sierra Eye Associates, as the panel delves into data from Stealth’s Phase 2 ReCLAIM-2 trial of elamipretide, specifically focusing on its application in dry age-related macular degeneration (dry AMD). Additionally, the leadership team will provide a comprehensive update on the Phase 3 development plans for elamipretide.
To be a part of this engaging session, register for the webcast by visiting the registration page [insert registration page link]. For those unable to attend the live event, a replay of the webcast will be available through Baird for a limited time.
About Stealth BioTherapeutics: Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to advancing the discovery, development, and commercialization of groundbreaking therapies targeting diseases associated with mitochondrial dysfunction. Mitochondria, crucial for energy production in the body, play a pivotal role in normal organ function. The company’s focus extends to rare genetic diseases and common age-related conditions, particularly those impacting organ systems with high energy demands like the eye, neuromuscular system, heart, and brain.
The lead product candidate, elamipretide, is progressing into Phase 3 clinical trials, with a particular emphasis on dry age-related macular degeneration and the pivotal NuPOWER trial in nPMM. Simultaneously, regulatory efforts continue for Phase 3 data in Barth syndrome, an ultra-rare cardioskeletal disease. Stealth is also evaluating its second-generation clinical-stage candidate, SBT-272, for indications in ophthalmic and neurological diseases based on promising preclinical data. With a robust pipeline of mitochondria-targeted compounds, the company is actively exploring therapeutic product candidates.
Stay tuned for groundbreaking insights and advancements in mitochondrial-targeted therapies from Stealth BioTherapeutics.